Avelumab and Merkel Cell Carcinoma: A Clinical Evidence Review

From General Health to Occupational Exposure Concerns

The legacy of general health and science information has long provided a foundational framework for understanding broad biological principles, including immune system function and disease prevention. Within this context, public health messaging has historically emphasized lifestyle factors and environmental exposures as key determinants of wellness. As scientific inquiry deepens, the focus naturally narrows from population-level guidance to specific clinical scenarios where therapeutic interventions intersect with occupational realities. In the domain of mass production, workers may encounter unique chemical or biological agents that warrant targeted investigation. The transition from general health awareness to a focused occupational exposure concern begins with recognizing that certain pharmaceuticals, once developed for clinical use, can become part of industrial or manufacturing environments. Avelumab, a monoclonal antibody approved for oncological applications, represents such a compound. Its use in treating Merkel cell carcinoma has prompted scrutiny not only of patient outcomes but also of potential exposure pathways for those involved in its production, handling, or administration. This pivot from a general health context to a specific exposure concern requires a careful review of clinical evidence to determine whether occupational contact with avelumab could influence the risk of developing Merkel cell carcinoma. The following discussion examines this causation hypothesis through a neutral, evidence-based lens, without invoking unsubstantiated mechanistic claims.

Clinical Profile of Avelumab and Merkel Cell Carcinoma

Avelumab (Bavencio) is a fully human IgG1 monoclonal antibody directed against programmed cell death ligand 1 (PD-L1) and functions as an immune checkpoint inhibitor (https://pubmed.ncbi.nlm.nih.gov/29799096/). It has been approved in the USA, the EU, and Japan for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive neuroendocrine cutaneous malignancy with poor prognosis (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/29799096/). Approval was based on the two-part, single-arm, phase II trial JAVELIN Merkel 200, in which confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC treated with avelumab (https://pubmed.ncbi.nlm.nih.gov/29799096/). Avelumab is the first therapeutic agent specifically approved for this indication and is approved independent of line of treatment (https://pubmed.ncbi.nlm.nih.gov/29799096/). Merkel cell carcinoma is a rare, highly aggressive skin cancer with neuroendocrine differentiation, associated with chronic exposure to ultraviolet light and the Merkel cell polyoma virus (https://pubmed.ncbi.nlm.nih.gov/35877101/; https://pubmed.ncbi.nlm.nih.gov/36450381/). The incidence rate of MCC is increasing, and it is associated with high rates of recurrence and mortality (https://pubmed.ncbi.nlm.nih.gov/35877101/). Immune checkpoint inhibitors (ICIs), including avelumab, offer durable responses and significant clinical benefit, with response rates to PD-1/PD-L1 inhibition of up to 62% (https://pubmed.ncbi.nlm.nih.gov/36450381/). Despite these advances, approximately 50% of patients with advanced MCC treated with ICI progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/).

Adverse Events and Causation Considerations

Checkpoint inhibitors including avelumab are known to cause overactivation of the immune system, leading to immune-related adverse events (irAEs) (https://pubmed.ncbi.nlm.nih.gov/31543781/). One reported case describes hypercalcaemia secondary to reactivation of sarcoidosis in a patient with metastatic MCC on avelumab; hypercalcaemia was managed with corticosteroids to full resolution, and avelumab therapy was safely continued (https://pubmed.ncbi.nlm.nih.gov/31543781/). This case illustrates that avelumab can trigger immune-mediated adverse events beyond typical organ-specific toxicities. For patients who become refractory to avelumab, efficient and safe treatment options are lacking (https://pubmed.ncbi.nlm.nih.gov/33439294/). In a multicenter study of the prospective skin cancer registry ADOREG, ipilimumab plus nivolumab was evaluated in avelumab-refractory MCC (https://pubmed.ncbi.nlm.nih.gov/36450381/). At three different sites in Germany, clinical and molecular data of patients with metastatic MCC refractory to avelumab and subsequently treated with combined ipilimumab/nivolumab were retrospectively collected (https://pubmed.ncbi.nlm.nih.gov/33439294/). Five patients were enrolled, and three out of five responded to combined therapy according to RECIST 1.1 (https://pubmed.ncbi.nlm.nih.gov/33439294/). A separate retrospective study of ipilimumab plus nivolumab in anti-PD-L1/PD-1 refractory MCC also noted that despite advances, approximately 50% of patients progress on ICI therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/). Regarding causation considerations, the timeline between avelumab exposure and documented harm is variable. Immune-related adverse events can occur at any point during treatment, as seen in the sarcoidosis reactivation case (https://pubmed.ncbi.nlm.nih.gov/31543781/). For MCC progression or refractoriness, the timeline is defined by clinical response assessments; patients who do not achieve objective response or who progress after initial response are considered refractory. The JAVELIN Merkel 200 trial established that approximately one-third of chemotherapy-refractory patients respond, meaning two-thirds do not achieve a confirmed objective response (https://pubmed.ncbi.nlm.nih.gov/29799096/). The adequacy of warnings regarding avelumab and MCC is reflected in the product labeling, which includes information on immune-mediated adverse events and the risk of treatment failure. However, given that approximately 50% of patients with advanced MCC progress on ICI therapy, including avelumab, the risk of non-response or progression is substantial (https://pubmed.ncbi.nlm.nih.gov/35877101/). For affected patients, causation considerations include whether the harm (e.g., disease progression, irAE) is attributable to avelumab or to the underlying disease. In the case of irAEs, the causal link is supported by the known mechanism of immune checkpoint inhibition and temporal association. For disease progression, the natural history of MCC must be considered, as it is a highly aggressive malignancy with poor prognosis independent of treatment (https://pubmed.ncbi.nlm.nih.gov/33439294/). In summary, avelumab is an effective therapy for metastatic MCC, but it carries risks of immune-related adverse events and a substantial rate of non-response or progression. Patients who become refractory have limited options, though combination immunotherapy may provide benefit in some cases. The evidence supports a causal relationship between avelumab and immune-mediated harms, while disease progression reflects both treatment failure and the aggressive nature of MCC.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is avelumab and how is it used in Merkel cell carcinoma?

Avelumab (Bavencio) is a fully human IgG1 monoclonal antibody that inhibits PD-L1, functioning as an immune checkpoint inhibitor. It is approved for the treatment of metastatic Merkel cell carcinoma (MCC) based on the JAVELIN Merkel 200 trial, which showed objective responses in about one-third of chemotherapy-refractory patients (https://pubmed.ncbi.nlm.nih.gov/29799096/).

What are the risks associated with avelumab treatment?

Avelumab can cause immune-related adverse events (irAEs) due to overactivation of the immune system, including cases like sarcoidosis reactivation (https://pubmed.ncbi.nlm.nih.gov/31543781/). Additionally, approximately 50% of patients with advanced MCC progress on immune checkpoint inhibitor therapy, including avelumab (https://pubmed.ncbi.nlm.nih.gov/35877101/).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Avelumab exposure and a confirmed Merkel Cell Carcinoma diagnosis may request an independent eligibility review. [Begin Assessment]

References

Check Whether Your Situation Qualifies

Free and confidential. No obligation — an initial records screening only.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.